{"sentence_labels": [-1, 1, -1, -1, -1, -1], "text": "This is a multicentre, randomized, double-blind, placebo-controlled, crossover trial of \u03c93 in children and adolescents with ASD, registered in the European Clinical Trials Database (EudraCT) under number 2007-006444-21. Stratified randomization was conducted with blocks of 4 subjects within each strata. Stratification took into account site and age (with 2 options, less than 12 years of age and 12 and above). Participants were randomized to receive treatment with \u03c93 PUFAs (experimental treatment) or paraffin oil (placebo) for 8 weeks (phase I). After a 2-week washout phase, participants receiving \u03c93 PUFAs in phase I switched to placebo and vice versa, and continued on them for 8 weeks more (phase II). Before and after phases I and II, blood draws and clinical evaluations were performed.", "section": "Design and treatment", "classification_label": 0, "section_number": 9, "sentences": ["This is a multicentre, randomized, double-blind, placebo-controlled, crossover trial of \u03c93 in children and adolescents with ASD, registered in the European Clinical Trials Database (EudraCT) under number 2007-006444-21.", "Stratified randomization was conducted with blocks of 4 subjects within each strata.", "Stratification took into account site and age (with 2 options, less than 12 years of age and 12 and above).", "Participants were randomized to receive treatment with \u03c93 PUFAs (experimental treatment) or paraffin oil (placebo) for 8 weeks (phase I).", "After a 2-week washout phase, participants receiving \u03c93 PUFAs in phase I switched to placebo and vice versa, and continued on them for 8 weeks more (phase II).", "Before and after phases I and II, blood draws and clinical evaluations were performed."], "doc_id": "37077"}